Evidence map›Paper›PMID 29333489›Full record

ArticleACS biomaterials science & engineering2016

Degradable acetalated dextran microparticles for tunable release of an engineered hepatocyte growth factor fragment.

Sophia L Suarez, Adam Muñoz, Aaron Mitchell, Rebecca L Braden, Colin Luo, Jennifer R Cochran, Adah Almutairi, Karen L Christman

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS biomaterials science & engineering, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Hydrogel Formation with Enzyme-Responsive Cyclic Peptides.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  4. Review
  5. Bioresponsive drug delivery systems for the treatment of inflammatory diseases.Journal of controlled release : official journal of the Controlled Release Society · 2020
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Sophia L SuarezDepartment of Bioengineering, University of California, San Diego, La Jolla, CA 92093, USA.
Adam MuñozDepartment of Bioengineering, University of California, San Diego, La Jolla, CA 92093, USA.
Aaron MitchellDepartment of Bioengineering, The Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA.
Rebecca L BradenDepartment of Bioengineering, University of California, San Diego, La Jolla, CA 92093, USA.
Colin LuoDepartment of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Jennifer R CochranDepartment of Chemical Engineering, The Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA.
Adah AlmutairiSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego, La Jolla, California 92093, USA.
Karen L ChristmanDepartment of Bioengineering, University of California, San Diego, La Jolla, CA 92093, USA.
University of California, San Diego · USStanford University · USUniversity of Montana · US

Funding

Graduate Training Program in BiotechnologyT32GM008412 · NIGMS · STANFORD UNIVERSITY · PI COCHRAN, JENNIFER R · 1991 to 2020
$5.5M
Autonomously Assembling Nanomaterial Scaffolds for Treating Myocardial InfarctionR01HL117326 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHRISTMAN, KAREN L, GIANNESCHI, NATHAN CLAUDE · 2012 to 2016
$1.9M
Engineered HGF-NK1 antagonists for Met-targeted cancer imaging and therapyR01CA151706 · NCI · STANFORD UNIVERSITY · PI COCHRAN, JENNIFER R · 2010 to 2014
$1.6M
Biomaterial enhancement of stem cell transplant efficacy for macular degenerationR01EY024134 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ALMUTAIRI, ADAH, ZHANG, KANG · 2014 to 2016
$1.1M
NCI NIH HHS R01 CA151706NEI NIH HHS R01 EY024134NHLBI NIH HHS R01 HL117326NIGMS NIH HHS T32 GM008412
6 · The paper itself

Abstract

Injectable biomaterials are promising as new therapies to treat myocardial infarction (MI). One useful property of biomaterials is the ability to protect and sustain release of therapeutic payloads. In order to create a platform for optimizing the release rate of cardioprotective molecules we utilized the tunable degradation of acetalated dextran (AcDex). We created microparticles with three distinct degradation profiles and showed that the consequent protein release profiles could be modulated within the infarcted heart. This enabled us to determine how delivery rate impacted the efficacy of a model therapeutic, an engineered hepatocyte growth factor fragment (HGF-f). Our results showed that the cardioprotective efficacy of HGF-f was optimal when delivered over three days post-intramyocardial injection, yielding the largest arterioles, fewest apoptotic cardiomyocytes bordering the infarct and the smallest infarcts compared to empty particle treatment four weeks after injection. This work demonstrates the potential of using AcDex particles as a delivery platform to optimize the time frame for delivering therapeutic proteins to the heart.

Indexed as

acetalated dextranHGFmicroparticlemyocardial infarctiontunable release

Identifiers

PMID29333489
PMCPMC5761072
OpenAlexW2474008740

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.